Chondroitin and joint pain

What 6 graded rows on chondroitin agree on for joint pain, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Chondroitin page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Chondroitin page, with its PubMed record.

Your question

Joint pain6

Supplement

Chondroitin Choose another

Chondroitin and joint pain

6 rows · 11,682 people

Split. 2 rows found an improvement, 2 found no difference and 2 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

Grade B× 2
Grade C× 2
No effect× 2

Rows: 6
Trials: 43
People: 11,682; Pooled reviews may count some twice

Where they differ

From the rows

Study design

The best-graded row, grade B, is a systematic review of 1,253 people (2015) and found an improvement. 2 rows are graded No effect, our grade for adequately powered trials that found no effect.

Only the 2 rows that found an improvement include pooled reviews of several trials (1 of 2); the 2 rows that found no difference are single studies.

2 rows with mixed results are left out of this comparison.

The rows

2 improved · 2 no difference · 2 mixed

Grade BOsteoarthritis pain (20% reduction, WOMAC) · Improved
Systematic review, 2 studies · n 1,253 · 2015 · Adults with knee osteoarthritis in the 2 low-risk-of-bias trials pooled for this outcome
Varied across trials · 1 month to 3 years across the review
53 of 100 on chondroitin versus 47 of 100 on placebo reached a 20% drop in knee pain (high-quality evidence); across all 43 trials pain scores were 10 points lower in short trials, but with low-quality, heterogeneous evidence.
Row on the Chondroitin page · PubMed 25629804 (opens PubMed)
Grade BKnee osteoarthritis pain and function (pharmaceutical-grade product) · Improved
RCT · n 604 · 2017 · Adults with symptomatic knee osteoarthritis in five European countries
800 mg/day (celecoxib 200 mg/day as active control) · 6 months (182 days)
Pain on a 100 mm scale fell 42.6 mm with chondroitin, 39.5 mm with celecoxib and 33.3 mm with placebo; chondroitin beat placebo for pain and function (Lequesne index) and did not differ from celecoxib. All treatments were well tolerated.
Row on the Chondroitin page · PubMed 28533290 (opens PubMed)
No effectKnee pain response (20% drop) · No difference
RCT · n 1,583 · 2006 · Adults with symptomatic knee osteoarthritis (mean age 59)
1,200 mg/day chondroitin (with or without 1,500 mg/day glucosamine) · 24 weeks
Response was 5.3 points higher than placebo for chondroitin alone (P=0.17) and 6.5 points for the combination (P=0.09), both not significant; celecoxib beat placebo. An exploratory moderate-to-severe pain subgroup did better on the combination.
Row on the Chondroitin page · PubMed 16495392 (opens PubMed)
No effectKnee pain and joint space narrowing over 2 years · No difference
RCT · n 605 · 2015 · Adults aged 45–75 with chronic knee pain and medial joint space narrowing (Australia)
800 mg/day chondroitin, with or without 1,500 mg/day glucosamine sulfate · 2 years
No group had less knee pain than placebo. Chondroitin alone did not slow joint space narrowing; the combination slowed it by 0.10 mm over 2 years (P=0.046). 6% of participants reported possibly related adverse events.
Row on the Chondroitin page · PubMed 24395557 (opens PubMed)
Grade COsteoarthritis pain (knee or hip) · Mixed
Meta-analysis, 20 studies · n 3,846 · 2007 · Adults with knee or hip osteoarthritis in 20 trials
Varied across trials · Varied across trials
Heterogeneity was very high (I² 92%); small and lower-quality trials showed larger benefits, and the 3 large intention-to-treat trials showed essentially no effect.
Row on the Chondroitin page · PubMed 17438317 (opens PubMed)
Grade CKnee osteoarthritis pain: pharmaceutical-grade vs other chondroitin · Mixed
Meta-analysis, 18 studies · n 3,791 · 2019 · Adults with osteoarthritis (mostly knee) in 18 placebo-controlled trials
Mostly 800 mg/day (400–2,000 mg/day across trials, from the full text) · 13 to 104 weeks (from the full text)
Across all trials pain fell (SMD −0.63) and function improved (SMD −0.82), but with extreme heterogeneity (I² 94–95%). In trials at low risk of bias, IBSA's pharmaceutical-grade chondroitin reduced pain (SMD −0.25) while other preparations did not (SMD −0.08, not significant); larger trials showed smaller effects.
Row on the Chondroitin page · PubMed 30879253 (opens PubMed)

Read onRead the full evidenceThe full evidence chapter on its page, with every outcome and its sources.